Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Peter Voorhees named associate director of clinical research at Wake Forest

Peter Voorhees was promoted to associate director of clinical research and will oversee clinical research for Atrium Health Wake Forest Baptist Comprehensive Cancer Center, as well as all processes related to clinical protocol and data management and protocol review and monitoring system.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves tafasitamab-cxix for r/r follicular lymphoma

FDA has approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to survive stress, according to new research from Children’s Medical Center Research Institute at UT Southwestern published in Nature.

June 13, 2025

Vol.51 No.23

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology.

Texas Oncology breaks ground on $120M cancer center in Plano

Texas Oncology on June 4 broke ground on a $120 million cancer center in Plano, marking a milestone for cancer care in North Texas.

June 06, 2025

Vol.51 No.22

Clinical Roundup

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

June 06, 2025

Vol.51 No.22

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

YOU MAY BE INTERESTED IN

Peter Voorhees named associate director of clinical research at Wake Forest

FDA approves tafasitamab-cxix for r/r follicular lymphoma

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Texas Oncology breaks ground on $120M cancer center in Plano

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

YOU MAY BE INTERESTED IN

Peter Voorhees named associate director of clinical research at Wake Forest

FDA approves tafasitamab-cxix for r/r follicular lymphoma

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher findsCells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Texas Oncology breaks ground on $120M cancer center in Plano

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Never miss an issue!

Login

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response